ankylosing spondylitis

Showing 7 posts of 7 posts found.


Gilead and Galapagos’ ankylosing spondylitis drug hits Phase 2 trial goal

September 7, 2018
Medical Communications, Research and Development Galapagos, Gilead, ankylosing spondylitis, filgotinib, pharma

Gilead and Galapagos have announced that their jointly-developed selective JAK1 inhibitor filgotinib has met its primary endpoint in a Phase …


NICE recommends Cosentyx in ankylosing spondylitis

August 4, 2016
Research and Development, Sales and Marketing Cosentyx, NICE, Novartis, ankylosing spondylitis

Novartis has announced that the National Institute for Health and Care Excellence (NICE) has recommended Cosentyx (secukinumab) to treat adults …

AS spine fusion

Novartis’ Cosentyx shows benefits in Phase III AS trials

January 4, 2016
Research and Development, Sales and Marketing Cosentyx, Novartis, Secukinumab, ankylosing spondylitis

Novartis says results from two Phase III studies for Cosentyx in ankylosing spondylitis (AS) showing significant clinical improvements versus placebo.Results …

Abbvie image

AbbVie highlights treatment adherence

June 12, 2014
Sales and Marketing ALIGN, AbbVie, Abbott, Crohn’s disease, TNF, ankylosing spondylitis, psoriasis, psoriatic arthritis, rheumatoid arthritis, treatment, ulcerative colitis

Patients with inflammatory diseases tend to be better at following their treatment regimes with TNF inhibitors rather than other medicines, …

NASS website

Abbott launches online tool for ankylosing spondylitis

April 23, 2012
Medical Communications AS, Abbott, NHS, NICE, ankylosing spondylitis

Abbott has launched a new online assessment tool that has the potential to change the landscape of ankylosing spondylitis (AS) …

MSD sways NICE with Simponi patient access scheme

August 26, 2011
Sales and Marketing NICE, Simponi, ankylosing spondylitis

A patient access scheme which lowers Simponi’s cost has led to Merck Sharp and Dohme’s drug being given the thumbs …

Sanofi eyes phase III move for sarilumab in rheumatoid arthritis

July 13, 2011
Research and Development Regeneron, Sanofi, ankylosing spondylitis, research and development news, rheumatoid arthritis, sarilumab

Sanofi is poised to move sarilumab into phase III trials for rheumatoid arthritis after the monoclonal antibody showed positive results …

Latest content